For the analysis of the pathophisiological role of the kallikrein system in hematological disorders, the system of bone marrow blood (BM) was examined. Using chromogenic peptide substrate (S-2302), spontaneous activity, prekallikrein activated by activator (KABI Co.) and kallikrein inhibitor to purified plasma kallikrein (KABI Co.), were measured in BM of 15 cases of hematological disorder.
Spontaneous activity was 13.5+4. 5 (mean+SD) u/L in peripheral blood (PB) and 36. 1+13.4 u/L in BM. Prekallikrein was 86.2+19.3 % (PB) and 72.6+ 20.6% (BM). Kallikrein inhibitor was 91.9+30.3 % (PB) and 55.4+21.5 % (BM). A good correlation between spontaneous activity and kallikrein inhibitor was observed in BM. Another good correlation between kallikrein inhibitor and C1-inactivator was observed both in PB and BM. The discrepancy between BM and PB was marked in acute leukemia. Prekallikrein and kallikrein inhibitor were depressed both in PB and BM in myeloprolif erative diseases.
Compared to PB, high spontaneous activity, depressed prekallekrein and depressed kallikrein inhibitor were obvious in BM. These suggest a marked activation of the kallikrein system in BM and a possible participation of kallikrein in hematopoietic enviroment. 
